Combined Therapy for Alcohol Use Disorder and PTSD
(CPT+RP Trial)
Trial Summary
What is the purpose of this trial?
The goal of this clinical trial is to test the efficacy of a novel integrative cognitive-behavioral intervention in patients with posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD). Specific Aim 1: Examine the efficacy of CPT-RP, as compared to RP alone, in reducing alcohol frequency (percent days drinking) and quantity (drinks per drinking day) as measured by the Timeline Follow-Back (TLFB). Specific Aim 2: Examine the efficacy of CPT-RP, as compared to RP alone, in reducing PTSD symptoms as measured by the Clinician Administered PTSD Scale (CAPS-5). Specific Aim 3: Use ecological momentary assessment (EMA) to evaluate intervention effects on daily alcohol-related cognitions and behaviors through real-time associations with PTSD symptomatology and distress tolerance. Researchers will compare integrative CPT+RP with RP-alone to see if CPT+RP is more efficacious in reducing alcohol use and PTSD symptom severity.
Will I have to stop taking my current medications?
If you are taking psychotropic medications, you need to be on a stable dose for at least 4 weeks before starting the study. If your medications were started in the past 4 weeks, you may not be eligible to participate.
What data supports the effectiveness of the treatment for Alcohol Use Disorder and PTSD?
Research shows that Cognitive Processing Therapy (CPT) is effective for PTSD, and when enhanced to address alcohol use, it can significantly improve both PTSD symptoms and alcohol-related problems. Integrated treatments combining cognitive-behavioral therapy for PTSD and substance use disorders have shown promise in reducing symptoms of both conditions.12345
Is the combined therapy for Alcohol Use Disorder and PTSD safe for humans?
How is the treatment Cognitive Processing Therapy + Relapse Prevention unique for treating PTSD and Alcohol Use Disorder?
This treatment is unique because it combines Cognitive Processing Therapy, which is effective for PTSD, with Relapse Prevention, which is used for Alcohol Use Disorder, into an integrated approach that addresses both conditions simultaneously, potentially improving outcomes for individuals with both PTSD and AUD.12378
Research Team
Sudie Back, PhD
Principal Investigator
Medical University of South Carolina
Anka A Vujanovic, Ph.D.
Principal Investigator
Texas A&M University
Eligibility Criteria
This trial is for adults aged 18-70 with both PTSD and moderate to severe alcohol use disorder, who can consent and understand English. It's not for those with bipolar disorder or other specific conditions. Participants should have a recent history of heavy drinking as defined in the study.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive 12, 90-minute individual sessions of CPT+RP or RP alone, delivered twice-weekly
Follow-up
Participants are monitored for changes in alcohol use and PTSD symptoms
Treatment Details
Interventions
- Cognitive Processing Therapy + Relapse Prevention (Behavioral Intervention)
- Relapse Prevention (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Houston
Lead Sponsor
Norman Sussman
University of Houston
Chief Medical Officer since 2020
MD from Baylor College of Medicine
Tom Luby
University of Houston
Chief Executive Officer since 2019
PhD in Immunology from the Sackler School of Biomedical Sciences, Tufts University
Texas A&M University
Lead Sponsor
Jeremy Gibson
Texas A&M University
Chief Medical Officer
MD
William “BJ” Jones
Texas A&M University
Chief Executive Officer
M.S. in Industrial Engineering from Texas A&M University
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Collaborator
Dr. George F. Koob
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Chief Executive Officer since 2014
PhD in Neurobiology from the Scripps Research Institute
Dr. Patricia Powell
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Chief Medical Officer since 2015
MD from an accredited institution
Medical University of South Carolina
Collaborator
Dr. Erik Summers
Medical University of South Carolina
Chief Medical Officer
MD from University of Alabama at Birmingham
Dr. Patrick J. Cawley
Medical University of South Carolina
Chief Executive Officer
MD, MBA